Skip to content

Evommune EVMN Initial Recognition Of Derivative Liability Upon Issuance

Initial Recognition Of Derivative Liability Upon Issuance at other companies

Alphatec Holdings logo
Alphatec HoldingsATEC
$0-100%
State Street logo
State StreetSTT
$254.98B-6.5%
Morgan Stanley logo
Morgan StanleyMS
$38.78B+44.3%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$50.26M+17.4%
Capital City Bank Group logo
Capital City Bank GroupCCBG
$5.32M0.0%
Raymond James Financial logo
Raymond James FinancialRJF
$61M-15.3%

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M
Total equity-$4.5M-3,048%
Total assets$7.2M

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$848.59M+39.5%
Enterprise value$849.52M
P/S127.3×

Profitability

See full
Gross margin53.7%
Operating margin-30.7%
Net margin-90.1%

Returns & leverage

See full
Return on equity275.7%
Debt / equity1.4×
Current ratio1.2×

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:InitialRecognitionOfDerivativeLiabilityUponIssuance.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's initial recognition of derivative liability upon issuance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evommune 's initial recognition of derivative liability upon issuance?
Evommune (EVMN) reported initial recognition of derivative liability upon issuance of $3.32M in Q4 2025.
What does initial recognition of derivative liability upon issuance mean?
The fair value assigned to a derivative liability at the time of its initial recognition on the balance sheet, often resulting from complex financing instruments like convertible notes or warrants. This metric highlights the upfront accounting impact of non-standard financing arrangements on the company's financial position.